Articles

The major bottleneck for research and development of radiopharmaceuticals for targeted alpha therapy is its limited availability. The irradiation of radium-226 could be a game changer as the amounts produced using this method could fulfill the market needs for alpha-emitters. However, there are several challenges in 226Ra target preparation and further processing of irradiated targets.

A decade ago, it was claimed that alpha-emitters are indispensable when it comes to optimisation of strategies for tumour therapy. Over time, this robust statement has become increasingly relevant, which has resulted in research aiming to develop alpha therapy which can be used in the clinic to substantially improve outcomes for cancer patients. This is exactly what healthcare entrepreneur Jan van Bodegom, MD will present at the 3rd Annual Targeted Radiopharmaceuticals (TRP) Summit in Berlin between 7 and 9 December 2021.